What Spritam Treats: Main Uses and Benefits

Spritam, which contains the active ingredient levetiracetam, is commonly used to help manage various symptoms of increased neurological or muscular activity in patients with epilepsy. The medication is applied across domains where additional symptomatic support is needed for managing three specific seizure patterns: partial-onset seizures (focal events), myoclonic seizures, and primary generalized tonic-clonic seizures (PGTC).

The medication may be part of symptomatic management as a sole treatment or as adjunctive therapy, supports patients during episodes of heightened discomfort, and contributes to easing the overall symptom load. For patients, the unique flash-dispersing structure of the Orally Disintegrating Tablet (ODT) is a practical feature of the medication.

“The ease of administration offered by the ODT formulation may assist with maintaining functional stability of the regimen.”

This formulation is particularly relevant in clinical settings where patients experience dysphagia (difficulty swallowing), such as some pediatric patients and older adults, which may assist with maintaining functional stability when symptoms interfere with routine activities related to administration.

---

Quick Fact: Relief for Recurrent Seizure Activity

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Exclusions

Regulatory agencies define specific population groups eligible to use Spritam (levetiracetam ODT) and list absolute contraindications. Eligibility is determined by patient age, body weight, and physiological status.

Absolute Contraindications

Classification	Exclusion Criteria (Must Not Use)
Hypersensitivity	Patients with a known allergy to levetiracetam or any of the product’s ingredients.

Eligibility Based on Age and Condition

Spritam is not approved for all age groups or patient conditions, with limits varying by seizure type:

• Pediatric Age Limits: Use is not indicated for Partial-Onset Seizures in children under 4 years of age or those weighing 20 kg or less. Minimum age eligibility is mathbfge 12 years for Myoclonic Seizures and mathbfge 6 years for Primary Generalized Tonic-Clonic Seizures.
• Organ Function Restrictions: Dosage adjustment is required for patients with renal impairment (kidney disease) and is advised for those with severe hepatic impairment (liver disease), as elimination of the medicine is reduced in these groups.
• Pregnancy and Lactation: Use during pregnancy necessitates close monitoring due to potential changes in drug plasma levels. Levetiracetam passes into human breast milk.

Spritam Interactions with other medicines and products

The official regulatory profile for Spritam (levetiracetam) defines its interaction structure primarily by the minimal risk of involvement with major metabolic pathways. The drug is unlikely to produce, or be subject to, pharmacokinetic interactions with the Cytochrome P450 (CYP) system or related enzymes like epoxide hydrolase. Consequently, co-administration with many antiepileptic medicines, including valproic acid, phenytoin, and lamotrigine, does not significantly affect the concentration of Spritam.

However, specific interaction patterns are documented:

• Pharmacodynamic Interaction: Co-administration with Alcohol or other central nervous system (CNS) depressants may result in an additive increase in CNS side effects such as somnolence.
• Exposure Modification: Enzyme-Inducing Antiepileptic Drugs (e.g., Carbamazepine) are documented to increase the apparent clearance of levetiracetam by approximately 22%. Conversely, co-administration with Methotrexate increases the plasma concentration of methotrexate.
• Food: Taking the medicine with food does not affect the total amount absorbed, but it formally decreases the maximum plasma concentration by 20% and delays the time to maximum concentration.
• Population Notes: Because the drug is mainly excreted unchanged by the kidneys, renal impairment reduces its clearance. A supplemental dose is required after hemodialysis, and plasma levels may be decreased during pregnancy.

How Spritam Works: Mechanism of Action

The mechanism of action for Spritam, whose active ingredient is Levetiracetam, is distinguished by its unique and highly specific interaction with a protein in the brain, which involves the modulation of neural network activity.

---

Targeted Modulation of Synaptic Vesicle Glycoprotein 2A ( SV2A)

Levetiracetam's action is initiated by its specific binding to the SV2A protein, which is embedded in the membranes of presynaptic vesicles. This interaction modulates the function of SV2A, thereby reducing the efficiency of synaptic vesicle exocytosis—the crucial step where chemical messengers are released into the synapse. The molecular action targets the regulatory steps of communication, limiting signal transmission.

---

Modulation of Pathological Neuronal Synchronicity

The reduced efficacy in vesicle release translates directly into a dampened release of excitatory neurotransmitters (such as glutamate) into the synaptic cleft. This decreases the overall excitatory tone in the brain and selectively counters the excessive, rapid, and synchronized electrical discharges that characterize neuronal instability. The resulting physiological effect is the establishment of altered neural network dynamics, which contributes to restricting the propagation of high-frequency electrical discharges. The mechanism exerts minimal influence on basal synaptic transmission.

How to Use Spritam: Official Administration Guidelines

Spritam (levetiracetam) is an orally disintegrating tablet (ODT) used under a strict regimen established by medical guidelines. This section details the administration protocol, dosing schedule, and specific handling requirements.

---

Administration and Dosage Frequency

Spritam is indicated for the oral route of administration. Its flash-dispersing form is also compatible with administration via a nasogastric (NG) tube or gastrostomy (G) tube after preparation.

Instruction Area	Official Guideline
Route of Administration	Oral or enteral tube administration
Dosing Frequency	Administered twice daily (every 12 hours)
Timing with Meals	May be taken with or without food

---

Standard Dosing and Titration

Treatment typically begins with a dose of 500 mg twice daily. The dosage is gradually increased, or titrated, by 500 mg twice daily approximately every two weeks until the recommended dose is reached. The maximum recommended dosage for adults across approved indications is 1,500 mg twice daily (3,000 mg per day).

Preparation and Special Instructions

• Preparation: The tablet is placed on the tongue and allowed to fully disperse before being swallowed with a sip of liquid. It is specified that patients must not swallow the tablet whole.
• Dose Adjustment: Dosage is individualized based on the patient's renal function (kidney clearance), and reduced doses are necessary in cases of renal impairment. Patients undergoing dialysis require a supplemental dose following the procedure.

Research Evidence / Overview of Studies for Spritam

Evidence for Use in Partial-Onset Seizures

Research has primarily focused on evaluating the active ingredient in Spritam, levetiracetam, in people experiencing partial-onset seizures. The core evidence comes from multiple short-term, multicenter Randomized Controlled Trials (RCTs). These studies largely examined levetiracetam as an adjunctive therapy—a treatment added to other existing medications—in patients whose seizures were refractory (not fully controlled).

Researchers monitored outcomes such as the change in seizure frequency measured over defined time intervals, and tracked the proportion of individuals who achieved a ge 50% reduction in seizure frequency during the study period. The findings describe patterns observed in these short-term trials, where the trials reported a higher proportion of participants in the active treatment groups achieving these measured reductions compared to those who received a placebo.

Evidence for Myoclonic Seizures and PGTC Seizures

Studies also explored the use of levetiracetam as an add-on treatment for two other specific types of seizures. For myoclonic seizures (in Juvenile Myoclonic Epilepsy) and Primary Generalized Tonic-Clonic (PGTC) seizures (in Idiopathic Generalized Epilepsy), research was conducted on adolescents, pediatric patients, and adults. These dedicated trials provide context regarding the specific changes measured in seizure frequency and seizure-free rates during the study period for both seizure types.

Studies Supporting the Unique Flash-Dispersing Tablet

Spritam is formulated as an Orally Disintegrating Tablet (ODT). Researchers conducted specific bioequivalence studies to compare this flash-dispersing form to the original, standard levetiracetam tablet. The research describes the comparable absorption patterns, providing assurance that the drug is available to the body despite the new physical form. The unique formulation was researched to address the needs of patients who experience difficulty swallowing, as it is designed to assist with functional stability related to administration.

Long-Term Evidence and Durability of Outcomes

The controlled, pivotal research for all indications focused on the measurement of short-term outcomes, typically lasting only 12 to 30 weeks. Therefore, the long-term effects are not fully established based on these controlled settings. While follow-up durations were limited, some participants were offered the option to participate in open-label extension studies for longer-term observation. The evidence quality varies across studies, and this type of research provides limited information for truly confirming the durability of outcomes over an extended time frame.

Key Studies & References

1. Study of Levetiracetam in Subjects with Refractory Partial Onset Seizures (N010)
2. Levetiracetam as Adjunctive Therapy in Juvenile Myoclonic Epilepsy (N011)
3. MedlinePlus Drug Information: Levetiracetam

Common questions about Spritam (FAQ)

---

Q: Does Spritam dissolve instantly or does it take a few minutes?

A: Official information describes Spritam as a flash-dispersing tablet, which means it is designed to disintegrate rapidly on the tongue. Regulatory guidance instructs the person taking the medicine to allow the tablet to fully disperse before swallowing it. While official sources do not specify an exact time in seconds, the intent is for quick breakdown.

Q: How quickly does Spritam start working for seizure control?

A: Pharmacokinetic studies indicate that the active ingredient is absorbed rapidly. Peak concentrations in the blood are typically reached about one hour after taking a dose when fasting. With a consistent twice-daily schedule, stable drug levels, known as 'steady-state,' are usually achieved within about two days.

Q: What kind of studies have been done on Spritam?

A: Clinical research for the active ingredient involves short-term, controlled trials for three specific seizure types, examining outcomes like the reduction in seizure frequency. Additionally, the unique flash-dispersing tablet form (ODT) underwent specific bioequivalence studies. These studies confirmed the drug is available to the body to the same degree as the standard tablet formulation.

Q: What is the risk of having an allergic reaction to Spritam?

A: The medicine is contraindicated (must not be used) if a patient has a known allergy or hypersensitivity to the active substance. Regulatory product information also describes rare but serious cutaneous (skin) reactions such as Stevens-Johnson Syndrome. Regulatory information includes warnings about seeking attention if signs of a serious reaction are observed.

Q: How long does Spritam stay in your system?

A: The drug's time in the body is primarily determined by its elimination rate, which is measured by its half-life. In healthy adults, the active ingredient's plasma half-life is documented as approximately 7 hours. The body removes the drug and its metabolite primarily through the kidneys.

Q: Does Spritam interact with common over-the-counter pain relievers?

A: Regulatory data indicates the drug is unlikely to cause major pharmacokinetic interactions because it is not significantly processed by the common liver enzyme system (CYP). Official documents highlight interactions with other seizure medicines and specific drugs like Methotrexate, but do not typically list specific, known clinically significant interactions with common over-the-counter pain relievers.

Q: What evidence supports the use of Spritam in pediatric patients?

A: Clinical trials provided evidence for the active ingredient's use in various seizure types across specific age ranges, including adolescents and younger children. This evidence documented the drug's effect in reducing seizure frequency in these pediatric populations for partial-onset, myoclonic, and primary generalized tonic-clonic seizures.

Q: What does the drug's safety classification indicate about its use?

A: As a type of Antiepileptic Drug (AED), the class carries a documented risk of increasing the potential for suicidal thoughts or behavior. Official information advises careful monitoring for any changes in mood, behavior, or the emergence of depression or suicidal thoughts.

Q: What happens if I forget to take a dose of Spritam?

A: Regulatory guidance on missed doses typically outlines the steps for resuming treatment and cautions against taking extra medicine. The general principle is to maintain a consistent schedule. Official prescribing information includes a warning that patients should not take two doses at once to compensate for a missed dose, emphasizing the need to follow the prescribed routine.

Q: Can I drive while taking Spritam?

A: Regulatory documents include a warning that due to the potential for somnolence (drowsiness) and coordination difficulties, individuals should not drive or operate complex machinery until they understand the medication's effect on them. This warning is included because these common side effects can impair alertness.

Q: Is Spritam known to interact with birth control pills?

A: Based on clinical study data, the drug is not documented to significantly alter the drug levels (pharmacokinetics) of oral contraceptives. The official product information indicates no statistically significant effect on the hormone concentrations found in standard birth control pills.

Q: Can Spritam be used by elderly patients?

A: The active ingredient is approved for use in adults, which includes the elderly population. Official data notes that dose adjustments may be necessary in older patients who experience a reduction in renal function (kidney clearance) with age. This adjustment is necessary because the drug's clearance relies on the kidneys.

Q: Are there generic versions of Spritam available?

A: The active ingredient, levetiracetam, is available in multiple generic and brand-name formulations that are chemically identical. However, Spritam is a specific brand-name Orally Disintegrating Tablet (ODT), a unique 3D-printed form, and the availability of a direct generic equivalent for this specific tablet structure may differ from the general availability of generic levetiracetam.

Q: Can men taking Spritam safely father children?

A: The active ingredient has been examined in studies related to the safety of anti-epileptic drugs taken by fathers. Research indicates that this drug is associated with a lower observed risk of neurodevelopmental disorders in children born to treated fathers compared to some other anti-epileptic compounds.

Q: Is it important to take Spritam at the exact same time every day?

A: The drug is administered on a twice-daily schedule, and regulatory information notes the importance of consistent dosing to help maintain steady drug concentrations for seizure control. This consistency involves spacing doses evenly throughout the day.

Q: What happens if a child accidentally takes an adult dose of Spritam?

A: Official prescribing information includes a section on overdose. Overdosing on the active ingredient may result in symptoms such as drowsiness, agitation, aggression, decreased consciousness, or coma. In the event of a suspected overdose, regulatory information highlights the need for immediate clinical intervention.

Q: Why do official documents state that Spritam should not be stopped suddenly?

A: Official documents state that the drug should be gradually reduced to lessen the risk of adverse outcomes. This precaution is necessary because the sudden discontinuation of the medication can lead to an increased frequency of seizures or the occurrence of withdrawal seizures.

Q: Are there specific patient groups where Spritam is less recommended?

A: Specific patient populations may require close attention or dose modification. This includes individuals with renal impairment (kidney disease) or severe hepatic impairment (liver disease), as the drug’s clearance is reduced in these conditions. Official information also notes that behavioral abnormalities have been reported more often in pediatric patients than in adults.

Q: Are there documented cases of overdose with Spritam?

A: Official prescribing information includes a dedicated section on Overdosage. This section describes the reported symptoms observed when the recommended dose is exceeded and outlines the appropriate medical management for such events.

Q: What are the typical benefits seen in clinical studies with Spritam?

A: In clinical studies, the measured benefit of the active ingredient was the reduction in the frequency of specific seizure types: partial-onset, myoclonic, and primary generalized tonic-clonic seizures. The results reported the proportion of participants who experienced a ge 50% reduction in seizure frequency.

Q: Does the 3D printing process make Spritam more effective?

A: Regulatory review focused on confirming the bioequivalence of the 3D-printed, flash-dispersing tablet (ODT) compared to the standard tablet. These studies found a comparable absorption pattern, meaning the drug is available to the body to the same extent. The key advantage of the ODT form is related to its ease of administration for specific patient needs, not enhanced effectiveness.

How to Store and Dispose of Spritam

Spritam (levetiracetam) must be stored at room temperature, specifically between 59°F and 86°F (15°C to 30°C). It does not require refrigeration. The tablets are supplied in child-resistant blister packs and should remain in their original packaging, away from moisture, and out of the reach of children.

When ready to use, the blister foil must be peeled back; do not push the tablet through the foil. The fast-dissolving tablet should be handled with dry hands. If the tablet is dispersed in a small volume of liquid for immediate administration, the dose must be consumed or administered right away.

For disposal of unused or expired medicine, follow standard drug disposal guidance. It is recommended to use an authorized drug take-back program. If a take-back program is not available, mix the tablets with an undesirable substance, place the mixture in a sealed container, and discard it in the household trash.